Innovative viral-vector platform for vaccines, oncolytic viruses and gene-therapy vectors; active virosome delivers up to 17 kb mRNA (six genes) and elicits humoral and cellular immune responses. Developing multivalent preclinical vaccine and oncolytic pipelines; open to partnering and co-development with biotech and pharmaceutical organizations.